Cargando…

Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage

Background: The overexpression of the human epidermal growth factor receptor-2 (HER2) gene is present in 20~25% of breast cancer (BC) patients, contributing to an inferior prognosis. Recent clinical trials showed that pyrotinib has promising antitumor activities and acceptable tolerability for those...

Descripción completa

Detalles Bibliográficos
Autores principales: Bao, Yuwen, Zhang, Zhuolin, He, Xuan, Cai, Lele, Wang, Xiao, Li, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497482/
https://www.ncbi.nlm.nih.gov/pubmed/36135045
http://dx.doi.org/10.3390/curroncol29090476
_version_ 1784794516196163584
author Bao, Yuwen
Zhang, Zhuolin
He, Xuan
Cai, Lele
Wang, Xiao
Li, Xin
author_facet Bao, Yuwen
Zhang, Zhuolin
He, Xuan
Cai, Lele
Wang, Xiao
Li, Xin
author_sort Bao, Yuwen
collection PubMed
description Background: The overexpression of the human epidermal growth factor receptor-2 (HER2) gene is present in 20~25% of breast cancer (BC) patients, contributing to an inferior prognosis. Recent clinical trials showed that pyrotinib has promising antitumor activities and acceptable tolerability for those patients (ClinicalTrials.gov, NCT03080805 and NCT02422199). Therefore, this study aims to assess the cost-effectiveness of pyrotinib plus capecitabine versus lapatinib plus capecitabine for patients with HER2-positive metastatic BC after prior trastuzumab. Methods: A lifetime-partitioned survival model was established to evaluate health and economic outcomes with different treatment strategies. The primary outcome was the incremental cost-effectiveness ratio (ICER). Data were derived from the published literature, clinical trials, expert opinions, and other local charges. Sensitivity analyses were performed to assess the robustness of the findings. Scenario analyses were developed to make further evaluations. Results: The pyrotinib regimen had significant advantages over the lapatinib regimen after enrolling in the National Reimbursement Drug List (NRDL), with cost savings of USD 15,599.27 and a gain of 0.53 QALYs. Meanwhile, before enrolling in NRDL, the pyrotinib regimen afforded the same QALYs at a higher incremental cost of USD 45,400.64 versus the lapatinib regimen, producing an ICER of USD 85,944.79 per QALY. Scenario analyses yielded similar results. Sensitivity analyses suggested stability in the cost-effectiveness findings. Conclusions: Compared to lapatinib plus capecitabine, the pyrotinib plus capecitabine enrolled in NRDL is a cost-effective alternative second-line treatment for patients with HER2-positive metastatic BC in China.
format Online
Article
Text
id pubmed-9497482
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94974822022-09-23 Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage Bao, Yuwen Zhang, Zhuolin He, Xuan Cai, Lele Wang, Xiao Li, Xin Curr Oncol Article Background: The overexpression of the human epidermal growth factor receptor-2 (HER2) gene is present in 20~25% of breast cancer (BC) patients, contributing to an inferior prognosis. Recent clinical trials showed that pyrotinib has promising antitumor activities and acceptable tolerability for those patients (ClinicalTrials.gov, NCT03080805 and NCT02422199). Therefore, this study aims to assess the cost-effectiveness of pyrotinib plus capecitabine versus lapatinib plus capecitabine for patients with HER2-positive metastatic BC after prior trastuzumab. Methods: A lifetime-partitioned survival model was established to evaluate health and economic outcomes with different treatment strategies. The primary outcome was the incremental cost-effectiveness ratio (ICER). Data were derived from the published literature, clinical trials, expert opinions, and other local charges. Sensitivity analyses were performed to assess the robustness of the findings. Scenario analyses were developed to make further evaluations. Results: The pyrotinib regimen had significant advantages over the lapatinib regimen after enrolling in the National Reimbursement Drug List (NRDL), with cost savings of USD 15,599.27 and a gain of 0.53 QALYs. Meanwhile, before enrolling in NRDL, the pyrotinib regimen afforded the same QALYs at a higher incremental cost of USD 45,400.64 versus the lapatinib regimen, producing an ICER of USD 85,944.79 per QALY. Scenario analyses yielded similar results. Sensitivity analyses suggested stability in the cost-effectiveness findings. Conclusions: Compared to lapatinib plus capecitabine, the pyrotinib plus capecitabine enrolled in NRDL is a cost-effective alternative second-line treatment for patients with HER2-positive metastatic BC in China. MDPI 2022-08-23 /pmc/articles/PMC9497482/ /pubmed/36135045 http://dx.doi.org/10.3390/curroncol29090476 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bao, Yuwen
Zhang, Zhuolin
He, Xuan
Cai, Lele
Wang, Xiao
Li, Xin
Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage
title Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage
title_full Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage
title_fullStr Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage
title_full_unstemmed Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage
title_short Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage
title_sort cost-effectiveness of pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of her2-positive metastatic breast cancer in china: a scenario analysis of health insurance coverage
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497482/
https://www.ncbi.nlm.nih.gov/pubmed/36135045
http://dx.doi.org/10.3390/curroncol29090476
work_keys_str_mv AT baoyuwen costeffectivenessofpyrotinibpluscapecitabineversuslapatinibpluscapecitabineforthetreatmentofher2positivemetastaticbreastcancerinchinaascenarioanalysisofhealthinsurancecoverage
AT zhangzhuolin costeffectivenessofpyrotinibpluscapecitabineversuslapatinibpluscapecitabineforthetreatmentofher2positivemetastaticbreastcancerinchinaascenarioanalysisofhealthinsurancecoverage
AT hexuan costeffectivenessofpyrotinibpluscapecitabineversuslapatinibpluscapecitabineforthetreatmentofher2positivemetastaticbreastcancerinchinaascenarioanalysisofhealthinsurancecoverage
AT cailele costeffectivenessofpyrotinibpluscapecitabineversuslapatinibpluscapecitabineforthetreatmentofher2positivemetastaticbreastcancerinchinaascenarioanalysisofhealthinsurancecoverage
AT wangxiao costeffectivenessofpyrotinibpluscapecitabineversuslapatinibpluscapecitabineforthetreatmentofher2positivemetastaticbreastcancerinchinaascenarioanalysisofhealthinsurancecoverage
AT lixin costeffectivenessofpyrotinibpluscapecitabineversuslapatinibpluscapecitabineforthetreatmentofher2positivemetastaticbreastcancerinchinaascenarioanalysisofhealthinsurancecoverage